Current status and perspectives of neoadjuvant therapy for pancreatic cancer
The multimodality therapy with surgery as the core has gradually become the standard therapy for pancreatic cancer without distant metastasis. At present, many large-sample retrospective clinical studies have shown the value of neoadjuvant therapy in pancreatic cancer, and many international guidelines have recognized neoadjuvant therapy as a fundamental part of pancreatic cancer treatment. There are many ongoing large-scale, prospective, multi-center clinical trials, and the primary results of several studies have shown that neoadjuvant therapy can increase the radical resection rate of tumor and improve overall survival. However, there are still controversies over the value of neoadjuvant therapy in pancreatic cancer, especially resectable pancreatic cancer. In addition, no consensus has been reached on the selection of neoadjuvant regimen, the duration of neoadjuvant therapy, and neoadjuvant regimen after surgery for pancreatic cancer. It is believed that with the appearance of high-level evidence, neoadjuvant therapy will be widely used in pancreatic cancer..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Linchuang Gandanbing Zazhi - 35(2019), 5, Seite 946-952 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
LIANG Tingbo [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Adjuvant |
|---|
| doi: |
10.3969/j.issn.1001-5256.2019.05.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ06835116X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ06835116X | ||
| 003 | DE-627 | ||
| 005 | 20230501211029.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2019 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3969/j.issn.1001-5256.2019.05.003 |2 doi | |
| 035 | |a (DE-627)DOAJ06835116X | ||
| 035 | |a (DE-599)DOAJ74ad75dabeb943fa9f7081144b1f8608 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 050 | 0 | |a RC799-869 | |
| 100 | 0 | |a LIANG Tingbo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current status and perspectives of neoadjuvant therapy for pancreatic cancer |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The multimodality therapy with surgery as the core has gradually become the standard therapy for pancreatic cancer without distant metastasis. At present, many large-sample retrospective clinical studies have shown the value of neoadjuvant therapy in pancreatic cancer, and many international guidelines have recognized neoadjuvant therapy as a fundamental part of pancreatic cancer treatment. There are many ongoing large-scale, prospective, multi-center clinical trials, and the primary results of several studies have shown that neoadjuvant therapy can increase the radical resection rate of tumor and improve overall survival. However, there are still controversies over the value of neoadjuvant therapy in pancreatic cancer, especially resectable pancreatic cancer. In addition, no consensus has been reached on the selection of neoadjuvant regimen, the duration of neoadjuvant therapy, and neoadjuvant regimen after surgery for pancreatic cancer. It is believed that with the appearance of high-level evidence, neoadjuvant therapy will be widely used in pancreatic cancer. | ||
| 650 | 4 | |a pancreatic neoplasms | |
| 650 | 4 | |a neoadjuvant therapy | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a adjuvant | |
| 650 | 4 | |a radiotherapy | |
| 653 | 0 | |a Diseases of the digestive system. Gastroenterology | |
| 773 | 0 | 8 | |i In |t Linchuang Gandanbing Zazhi |d Editorial Department of Journal of Clinical Hepatology, 2017 |g 35(2019), 5, Seite 946-952 |w (DE-627)DOAJ000064300 |x 10015256 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2019 |g number:5 |g pages:946-952 |
| 856 | 4 | 0 | |u https://doi.org/10.3969/j.issn.1001-5256.2019.05.003 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/74ad75dabeb943fa9f7081144b1f8608 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.lcgdbzz.org/down.asp?id=9849 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1001-5256 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1001-5256 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2019 |e 5 |h 946-952 | ||